Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings

References

• GOLD. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD – 2020 report; 2020 [cited 2020 Apr 22]. Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf
   Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–1294.
   PubMed Web of Science ®Google Scholar
• Choudhury AB, Dawson CM, Kilvington HE, et al. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir Res. 2007;8:93.
   PubMed Web of Science ®Google Scholar
• Wouters EF, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax. 2005;60(6):480–487. .
   PubMed Web of Science ®Google Scholar
• van der Valk P, Monninkhof E, van der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med. 2002;166(10):1358–1363.
   PubMed Web of Science ®Google Scholar
• O’Brien A, Russo-Magno P, Karki A, et al. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med. 2001;164(3):365–371.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Roisin R, Tetzlaff K, Watz H, et al. Daily home-based spirometry during withdrawal of inhaled corticosteroid in severe to very severe chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2016;11:1973–1981.
   PubMed Web of Science ®Google Scholar
• Rossi A, van der Molen T, Del Olmo R, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014;44(6):1548–1556.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329–339.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Matera MG, Braido F, et al. Withdrawal of inhaled corticosteroids in COPD: a meta-analysis. Pulm Pharmacol Ther. 2017;45:148–158.
   PubMed Web of Science ®Google Scholar
• Oshagbemi OA, Odiba JO, Daniel A, et al. Absolute blood eosinophil counts to guide inhaled corticosteroids therapy among patients with COPD: systematic review and meta-analysis. Curr Drug Targets. 2019;20(16):1670–1679.
   PubMed Web of Science ®Google Scholar
• Scichilone N, Basile M, Battaglia S, et al. What proportion of chronic obstructive pulmonary disease outpatients is eligible for inclusion in randomized clinical trials? Respiration. 2014;87(1):11–17.
   PubMed Web of Science ®Google Scholar
• Travers J, Marsh S, Caldwell B, et al. External validity of randomized controlled trials in COPD. Respir Med. 2007;101(6):1313–1320. .
   PubMed Web of Science ®Google Scholar
• Ye W, Guo X, Yang T, et al. Systematic review of inhaled corticosteroid withdrawal effects in chronic obstructive pulmonary disease, and comparison with two “real-life” studies. J Thorac Dis. 2018;10(7):4565–4573.
   PubMed Web of Science ®Google Scholar
• Anzueto A, Kaplan A. Dual bronchodilators in chronic obstructive pulmonary disease: evidence from randomized controlled trials and real-world studies. Respir Med. 2020;2:100016.
   Google Scholar
• Bernstein JA, Kavati A, Tharp MD, et al. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ‘real-world’ evidence. Expert Opin Biol Ther. 2018;18(4):425–448.
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1). DOI:https://doi.org/10.1186/2046-4053-4-1.
   Google Scholar
• Schardt C, Adams MB, Owens T, et al. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007;7:16.
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Mullerova H, Hurst JR, et al. Validation of the recording of acute exacerbations of COPD in UK primary care electronic healthcare records. PloS One. 2016;11(3):e0151357.
   PubMed Web of Science ®Google Scholar
• Harries TH, Rowland V, Corrigan CJ, et al. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis. Respir Res. 2020;21(1):3.
   PubMed Web of Science ®Google Scholar
• Cataldo D, Derom E, Liistro G, et al. Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice. Int J Chron Obstruct Pulmon Dis. 2018;13:2089–2099.
   PubMed Web of Science ®Google Scholar
• Avdeev S, Aisanov Z, Arkhipov V, et al. Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms. Int J Chron Obstruct Pulmon Dis. 2019;14:1267–1280.
   PubMed Web of Science ®Google Scholar
• Kaplan AG. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice. Int J Chron Obstruct Pulmon Dis. 2015;10:2535–2548.
   PubMed Web of Science ®Google Scholar
• Oshagbemi OA, Franssen FME, van Kraaij S, et al. Blood eosinophil counts, withdrawal of inhaled corticosteroids and risk of COPD exacerbations and mortality in the clinical practice research datalink (CPRD). Copd. 2019;16(2):152–159.
   PubMedGoogle Scholar
• Schermer TR, Hendriks AJ, Chavannes NH, et al. Probability and determinants of relapse after discontinuation of inhaled corticosteroids in patients with COPD treated in general practice. Primary Care Respir J. 2004;13(1):48–55.
   PubMedGoogle Scholar
• Suissa S, Coulombe J, Ernst P. Discontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumonia. Chest. 2015;148(5):1177–1183. .
   PubMed Web of Science ®Google Scholar
• Jarad NA, Wedzicha JA, Burge PS, et al. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE study group. Respir Med. 1999;93(3):161–166.
   PubMed Web of Science ®Google Scholar
• Kunz LIZ, Postma DS, Klooster K, et al. Relapse in FEV1 decline after steroid withdrawal in COPD. Chest. 2015;148(2):389–396.
   PubMed Web of Science ®Google Scholar
• Rossi A, Guerriero M, Corrado A. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res. 2014;15(1):77.
   PubMedGoogle Scholar
• Vogelmeier C, Worth H, Buhl R, et al. “Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD. Int J Chron Obstruct Pulmon Dis. 2017;12:487–494.
   PubMed Web of Science ®Google Scholar
• Lee SH, Lee JH, Yoon HI, et al. Change in inhaled corticosteroid treatment and COPD exacerbations: an analysis of real-world data from the KOLD/KOCOSS cohorts. Respir Res. 2019;20(1):62. .
   PubMedGoogle Scholar
• Greulich T, Kostikas K, Gaga M, et al. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. Int J Chron Obstruct Pulmon Dis. 2018;13:1229–1237.
   PubMed Web of Science ®Google Scholar
• Kaplan A, Chapman KR, Anees SM, et al. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study. Int J Chron Obstruct Pulmon Dis. 2019;14:249–260.
   PubMed Web of Science ®Google Scholar
• Worth H, Buhl R, C-P C, et al. GOLD 2017 treatment pathways in ‘real life’: an analysis of the DACCORD observational study. Respir Med. 2017;131:77–84.
   PubMed Web of Science ®Google Scholar
• NCT01985334. Study to evaluate the efficacy and safety of glycopyrronium or indacaterol maleate and glycopyrronium bromide fixed-dose combination regarding symptoms and health status in patients with moderate COPD switching from treatment with any standard COPD regimen; 2013 [cited 2020 May 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT01985334
   Google Scholar
• NCT02202616. Prospective cohort study for the real - life effectiveness evaluation of GlycOpyrronium with IndacatERol combination in the management of COPD in Canada (POWER Study) (POWER); 2014 [cited 2020 May 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT02202616
   Google Scholar
• NCT00158847. Modification of disease outcome in COPD; 2005 [cited 2020 May 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT00158847
   Google Scholar
• Cazzola M, Rogliani P, Matera MG. Escalation and De-escalation of Therapy in COPD: myths, realities and perspectives. Drugs. 2015;75(14):1575–1585.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Laska IF, Franssen FME, et al. Withdrawal of inhaled corticosteroids in chronic obstructive pulmonary disease: a European respiratory society guideline. Eur Respir J. 2020;55:2000351.
   Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Calzetta L, et al. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018;52(6):1801586.
   Web of Science ®Google Scholar
• Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10:2207–2217.
   PubMed Web of Science ®Google Scholar
• Blonde L, Khunti K, Harris SB, et al. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763–1774.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Ritondo BL, Matera MG, et al. Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review. Expert Rev Respir Med. 2020;14(6):621–635. DOI:https://doi.org/10.1080/17476348.2020.1743180
   Google Scholar
• Calzetta L, Cazzola M, Matera MG, et al. Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple combination therapy in COPD. Chest. 2019;155(4):758–770.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Matera MG, Ritondo BL, et al. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: a bidimensional comparative analysis across fixed-dose combinations. Pulm Pharmacol Ther. 2019;59:101841.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671–1680.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(12):1508–1516. .
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65(8):719–725.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26. .
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817–1826.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Cazzola M, Calzetta L. Cardiovascular disease in chronic respiratory disorders and beyond. J Am Coll Cardiol. 2019;73(17):2178–2180.
   PubMed Web of Science ®Google Scholar